TTNP - Titan Pharmaceuticals Inc Stock Price, Fair Value and News

6.55USD-0.01 (-0.15%)Delayed as of 15 May 2024, 01:47 pm ET

Market Summary

USD6.55-0.01

Delayedas of 15 May 2024, 01:47 pm

-0.15%

TTNP Stock Price

View Fullscreen

TTNP RSI Chart

TTNP Valuation

Market Cap

6.0M

Price/Earnings (Trailing)

-1.08

Price/Sales (Trailing)

32.59

Price/Free Cashflow

-0.85

TTNP Price/Sales (Trailing)

TTNP Profitability

Return on Equity

-83.85%

Return on Assets

-68.87%

Free Cashflow Yield

-118.29%

TTNP Fundamentals

TTNP Revenue

Revenue (TTM)

184.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

TTNP Earnings

Earnings (TTM)

-5.6M

Earnings Growth (Yr)

39.05%

Earnings Growth (Qtr)

-110.22%

Breaking Down TTNP Revenue

52 Week Range

6.55

(Low)(High)

Last 7 days

-2.7%

Last 30 days

-9.6%

Last 90 days

-3.5%

Trailing 12 Months

-56.8%

How does TTNP drawdown profile look like?

TTNP Financial Health

Current Ratio

5.55

TTNP Investor Care

Shares Dilution (1Y)

21.77%

Diluted EPS (TTM)

-9.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	463.5K	396.5K	304.5K	184.0K
2022	1.0M	741.0K	572.0K	557.5K
2021	4.4M	3.6M	2.8M	1.5M
2020	2.8M	3.5M	3.6M	4.8M
2019	5.5M	4.3M	3.6M	2.6M
2018	1.2M	3.8M	4.8M	6.6M
2017	11.4M	7.6M	3.9M	215.0K
2016	0	15.8M	15.0M	15.1M
2015	3.6M	3.5M	2.6M	1.7M
2014	6.2M	4.9M	3.6M	3.6M
2013	11.0M	11.9M	12.8M	10.5M
2012	4.4M	5.1M	5.3M	7.1M
2011	8.9M	6.5M	5.3M	4.1M
2010	0	0	0	10.1M
2009	0	0	0	0
2008	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Titan Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	choong choon hau	acquired	-	-	54,132	-
Oct 25, 2023	ben-tzvi avraham	acquired	-	-	16,250	-
Oct 25, 2023	greenberg eric howard	acquired	-	-	16,250	-
Oct 25, 2023	mcmurdo matthew charles	acquired	-	-	16,250	-
Oct 25, 2023	beebe katherine	acquired	-	-	16,250	president and coo
Oct 25, 2023	natan david	acquired	-	-	16,250	-
Jul 26, 2023	chasey peter louis	acquired	-	-	50,000	-
Jul 26, 2023	ben-tzvi avraham	acquired	-	-	50,000	-
Jul 26, 2023	greenberg eric howard	acquired	-	-	50,000	-

Which funds bought or sold TTNP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	TRUIST FINANCIAL CORP	sold off	-100	-257,849	-	-%
May 13, 2024	TRUIST FINANCIAL CORP	new	-	223,786	223,786	-%
May 13, 2024	UBS Group AG	sold off	-100	-1.00	-	-%
May 13, 2024	UBS Group AG	new	-	7.00	7.00	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-29,022	-	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-56,000	-	-%
May 10, 2024	OSAIC HOLDINGS, INC.	sold off	-100	-13.00	-	-%
May 10, 2024	JPMORGAN CHASE & CO	sold off	-100	-64.00	-	-%
May 10, 2024	VANGUARD GROUP INC	sold off	-100	-33,846	-	-%
May 10, 2024	BlackRock Inc.	sold off	-100	-25.00	-	-%

Are Funds Buying or Selling TTNP?

Are funds buying TTNP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TTNP

No. of Funds

Unveiling Titan Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	sire group ltd.	14.1%	150,087	SC 13D/A
Oct 04, 2023	sire group ltd.	16.7%	3,001,757	SC 13D
Jul 21, 2023	choong choon hau	24.95%	3,747,968	SC 13D
Jun 23, 2023	activist investing llc	0%	0	SC 13D/A
Dec 15, 2022	activist investing llc	25.2%	3,690,468	SC 13D/A
Aug 17, 2022	activist investing llc	25.2%	3,690,468	SC 13D/A
Jul 08, 2022	activist investing llc	25.2%	3,690,468	SC 13D/A
Jun 09, 2022	activist investing llc	9.9%	1,441,278	SC 13D/A
Apr 25, 2022	activist investing llc	5.6%	673,211	SC 13D
Feb 14, 2022	l1 capital global opportunities master fund, ltd.	4.99%	494,716	SC 13G/A

Recent SEC filings of Titan Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	RW	RW
Apr 05, 2024	SC 13D/A	13D - Major Acquisition
Apr 05, 2024	3	Insider Trading
Apr 05, 2024	3	Insider Trading
Apr 03, 2024	8-K	Current Report
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 27, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report
Feb 08, 2024	8-K	Current Report

Peers (Alternatives to Titan Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.91	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.98	9.54	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.39	14.63	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.02	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Titan Pharmaceuticals Inc News

Latest updates

Titan Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	3.00	83.00	98.00	121	95.00	150	192	135	264	445	682	1,445	1,018	1,249	1,126	211	947	502	945	1,236
Costs and Expenses	-100.0%	-	2,471	1,671	1,795	-	2,738	2,592	2,731	2,624	2,172	2,770	3,314	3,901	2,214	2,867	3,101	-4,963	4,830	5,384	5,230	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,230	4,503
S&GA Expenses	-49.3%	1,038	2,047	1,229	1,234	1,289	1,806	1,618	1,322	1,648	979	1,035	1,327	1,856	1,327	1,223	1,289	-3,935	3,023	3,231	3,082	2,358
R&D Expenses	14.7%	487	424	442	561	1,443	932	974	1,409	976	1,193	1,646	1,877	1,573	887	1,644	1,812	-290	1,619	1,907	1,844	1,855
Interest Expenses	-	17.00	-	-	-	-	-	-	-	-	-	-	-	-	97.00	96.00	102	104	109	110	109	127
Net Income	-110.2%	-1,564	-744	-1,586	-1,675	-2,566	-2,638	-2,462	-2,540	-2,540	-1,915	-1,680	-2,641	-3,085	-4,932	-4,641	-5,584	-3,941	-2,803	-5,197	-4,517	-3,504
Net Income Margin	-49.5%	-30.27*	-20.25*	-21.35*	-20.15*	-18.31*	-17.80*	-12.76*	-8.37*	-5.75*	-3.29*	-3.44*	-3.48*	-3.77*	-5.30*	-	-	-	-	-	-	-
Free Cashflow	-22.1%	-2,246	-1,840	-1,117	-1,904	-1,584	-1,878	-1,772	-2,969	-1,086	-2,262	-1,949	-2,625	-4,570	-3,891	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-19.1%	8,086	9,999	812	2,168	4,058	6,276	8,319	10,318	7,994	9,637	11,507	13,824	8,087	8,018	9,762	13,262	9,522	5,304	6,761	11,440	14,095
Current Assets	-19.0%	8,018	9,899	498	1,785	3,603	5,747	7,713	9,633	7,229	8,845	10,630	13,189	7,328	6,649	8,690	12,146	8,308	3,946	5,493	10,089	13,301
Cash Equivalents	-16.5%	6,760	8,096	105	1,136	2,937	4,450	6,420	8,138	6,332	7,418	9,680	11,629	5,413	4,073	5,498	8,038	5,223	921	2,292	5,909	9,656
Inventory	-	-	-	-	106	106	460	469	293	293	129	129	218	328	1,073	969	1,064	563	1,309	1,317	1,246	1,262
Net PPE	-16.7%	5.00	6.00	9.00	181	224	269	317	368	420	468	524	563	618	1,161	799	780	817	752	754	782	794
Liabilities	-22.6%	1,444	1,866	1,846	2,480	2,695	2,726	2,652	2,436	2,856	2,141	2,760	3,844	4,555	8,915	8,202	7,986	8,089	7,964	7,332	8,385	7,264
Current Liabilities	-22.6%	1,444	1,866	1,846	2,447	2,630	2,630	2,524	2,278	2,669	1,925	2,516	3,756	4,223	5,877	4,857	4,410	3,600	3,482	4,342	4,761	3,452
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	88.00	332	3,038	3,345	3,500	4,019	3,872	2,698	3,242	3,787
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	572	327	2,082	1,624	667	-	-	1,333	1,227	527
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	88.00	332	3,038	3,345	3,500	4,019	3,872	2,698	3,242	3,787
Shareholder's Equity	-18.3%	6,642	8,133	-	-	1,363	3,550	5,667	7,882	5,138	7,496	8,747	9,980	3,532	-	1,560	5,276	1,433	-	-	3,055	6,831
Retained Earnings	-0.4%	-391,830	-390,266	-389,522	-387,936	-386,261	-383,695	-381,057	-378,595	-376,055	-373,515	-371,600	-369,920	-367,279	-364,194	-359,262	-354,621	-349,037	-345,096	-342,293	-337,096	-332,579
Additional Paid-In Capital	0.0%	398,470	398,383	388,473	387,609	387,623	387,230	386,709	386,465	381,183	381,001	380,337	379,890	370,804	363,180	360,725	359,804	350,468	342,419	341,708	340,138	339,397
Shares Outstanding	-94.8%	782	15,016	751	751	751	731	685	602	496	493	493	464	357	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	7,300	-	-	-	25,600	-	-	-	29,700	-	-	-	17,300	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	17.9%	-1,840	-2,241	-1,112	-1,899	-1,579	-1,873	-1,767	-2,964	-1,081	-2,262	-1,931	-2,625	-4,561	-3,447	-3,983	-5,212	-3,663	-3,325	-4,149	-4,308	-3,308
Share Based Compensation	-88.3%	48.00	411	264	290	-91.00	27,000	27.00	253	146	9.00	447	248	3.00	9.00	79.00	-84.00	-42.00	128	350	136	335
Cashflow From Investing	-	504	-	-	-	-	-	-	-	-5.00	-	-18.00	-	-9.00	-444	-57.00	-30.00	-112	-61.00	-39.00	-44.00	-345
Cashflow From Financing	-	-	-	-	-	-	-	3.00	4,981	-	-	-	8,841	5,910	2,466	1,500	8,057	8,077	2,015	571	605	4,521

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TTNP Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenues	$ 184	$ 557
Operating expenses:
Research and development	1,913	4,758
General and administrative	5,548	6,034
Total operating expenses	7,461	10,792
Loss from operations	(7,277)	(10,235)
Other income (expense):
Interest income, net	5	53
Other expense, net	(52)	(24)
Gain on asset sale	1,755
Other income, net	1,708	29
Net loss	$ (5,569)	$ (10,206)
Basic net loss per common share	$ (7.41)	$ (15.19)
Diluted net loss per common share	$ (7.41)	$ (15.19)
Weighted average shares used in computing basic net loss per common share	752	672
Weighted average shares used in computing diluted net loss per common share	752	672
License and Service [Member]
Total revenues	$ 1	$ 60
Grant [Member]
Total revenues	$ 183	$ 497

TTNP Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 6,760	$ 8,096	$ 2,937
Restricted cash	13	13	196
Receivables	46	26	36
Notes receivable	1,000	1,500
Inventories	(0)		106
Prepaid expenses and other current assets	199	244	314
Discontinued operations - current assets		20	14
Total current assets	8,018	9,899	3,603
Property and equipment, net	5	6	224
Other assets			48
Operating lease right-of-use asset	63	94	183
Total assets	8,086	9,999	4,058
Current liabilities:
Accounts payable	348	407	695
Note payable to related party	500	500
Other accrued liabilities	519	790	1,488
Operating lease liability, current	65	97	122
Deferred grant revenue	12	12	196
Discontinued operations - current liabilities		60	129
Total current liabilities	1,444	1,866	2,630
Operating lease liability, non-current			65
Total liabilities	1,444	1,866	2,695
Stockholders’ equity:
Preferred stock, at amounts paid-in, $0.001 par value per share; 5,000,000 shares authorized, 950,000 shares issued and outstanding at December 31, 2023 and no shares issued and outstanding at December 31, 2022.	1	1
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 781,503 and 750,815 shares issued and outstanding at December 31, 2023 and 2022, respectively.	1	15	1
Additional paid-in capital	398,470	398,383	387,623
Accumulated deficit	(391,830)	(390,266)	(386,261)
Total stockholders’ equity	6,642	8,133	1,363	$ 5,138
Total liabilities and stockholders’ equity	$ 8,086	$ 9,999	$ 4,058

About Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

CEO	Mr. David Elliot Lazar
WEBSITE	titanpharm.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Titan Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Titan Pharmaceuticals Inc? What does TTNP stand for in stocks?

TTNP is the stock ticker symbol of Titan Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Titan Pharmaceuticals Inc (TTNP)?

As of Tue May 14 2024, market cap of Titan Pharmaceuticals Inc is 6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TTNP stock?

You can check TTNP's fair value in chart for subscribers.

What is the fair value of TTNP stock?

You can check TTNP's fair value in chart for subscribers. The fair value of Titan Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Titan Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TTNP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Titan Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TTNP is over valued or under valued. Whether Titan Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Titan Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TTNP.

What is Titan Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, TTNP's PE ratio (Price to Earnings) is -1.08 and Price to Sales (PS) ratio is 32.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TTNP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Titan Pharmaceuticals Inc's stock?

In the past 10 years, Titan Pharmaceuticals Inc has provided -0.531 (multiply by 100 for percentage) rate of return.